CC
TCRX icon

Cannell Capital’s TScan Therapeutics TCRX Stock Holding History

Cannell Capital’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,666
Closed -$30.8K – 82
2023
Q1 		$30.8K Hold
14,666
– – 0.01% 80
2022
Q4 		$22.7K Hold
14,666
– – ﹤0.01% 86
2022
Q3 		$45K Buy
14,666
+11,012
+301% +$36.1K 0.01% 70
2022
Q2 		$11K Buy
+3,654
New +$10K ﹤0.01% 80

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Cannell Capital's TCRX Position: Q2 2023 in Review

Cannell Capital sold out of TScan Therapeutics (TCRX) in Q2 2023, closing a stake of 14,666 shares — an estimated $30.8K sold.

Cannell Capital first reported a position in TCRX in Q2 2022 and held it in 4 quarters. The position peaked at $45K in Q3 2022. 28 funds tracked by Wall St. Rank hold TCRX as of Q2 2023.

  • Cannell Capital reported no remaining TScan Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cannell Capital sold 14,666 TScan Therapeutics shares in Q2 2023, an estimated $30.8K.
  • Cannell Capital first reported a position in TScan Therapeutics in Q2 2022 and held it in 4 quarters.
  • Cannell Capital's TScan Therapeutics position peaked at $45K in Q3 2022.
  • 28 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.